Novartis Ag

Novartis Pharma Gmbh

Maurice Van Eis

Taeyoung Yoon

Peter Von Matt

Jürgen Wagner

Nigel Graham Cooke

Jean-Pierre Evenou

Rudolf Duthaler

Erik Meredith

Gebhard Thoma

Christoph Gaul

Walter Schuler

Peter Buehlmayer

Gerhard Zenke

Klaus Hinterding

Anette Von Matt

Rita Ramos

Alexander Baxter Smith

Rolf Baenteli

Michael Paul Capparelli

Karen Kammertoens

Marie Claude Bernhard

Louis Walliser

Markus Rolf Dobler

Sarah Siska

Jr Charles Francis Jewell

The present invention relates to bicyclic heteroaryl cycloalkyldiamine derivatives, to processes for their production, to their use as SYK inhibitors and to pharmaceutical compositions comprising them. Formula (I) 

Bicyclic heteroaryl cycloalkyldiamine derivatives

The present invention relates to monocyclic heteroaryl cycloalkyldiamine derivatives of formula (I), to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them. 

Monocyclic heteroaryl cycloalkyldiamine derivatives

The present invention relates to substituted indole derivatives, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Substituted indole derivatives

A compound of formula (I) wherein R denotes another heterocyclic residue and wherein R, R, R, Rand R, are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.

Indolylmaleimide derivatives processes for their production and pharmaceutical compositions

A compound of formula (I), wherein R, R, R, ring A, which ring contains one or two nitrogen atoms, and ring B are as defined in the Specification, pharmaceutical compositions containing these compounds, and uses for these compounds and compositions, in particular, in transplantation. 

Indolymaleimide derivatives

Disclosed are pyrimidine derivatives of formula wherein R, R, Rto R, and Z have a signification as indicated in claim, which have interesting pharmaceutical properties.

2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors

A compound of formula (I) wherein R denotes another heterocylic residue and wherein R, R, R, Rand R, are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.

A compound of formula I wherein R, Rand Rare as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.

Substituted pyrrole-2, 5-diones as protein kinase C inhibitors

A compound of formula (I) wherein R, R, and R, ring A and ring B are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.

Indolylmaleimide derivatives

A compound of formula I wherein R, R, R, R, Rand Rare as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.

Disclosed are pyrimidine derivatives of formula wherein R, R, Rto R, and Z have a signification as indicated in claimwhich have interesting pharmaceutical properties.

2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors

This invention relates to PKC inhibitors which are able to selectively inhibit e.g. the and optionally 0, isoforms of PKC, and their use in particular in transplantation.

Growing community of inventors

St. Louis, France

Maurice Van Eis